Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Emergent BioSolutionsSTU:ER4 +4.79%61 Return-on-Tangible-Equity is 39.51% as of Mar. 2026, which is 151% above its 10-year median of 15.71. GuruFocus rates STU:ER4 with a GF Score™ of 61/100 and a GF Value™ of €4.15 (Significantly Overvalued). The stock has 5 warning signs investors should review. Among 901 Drug Manufacturers companies, Emergent BioSolutions ranks worse than 81.47% on this metric.
Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. Emergent BioSolutions's annualized net income for the quarter that ended in Mar. 2026 was €23.5 Mil. Emergent BioSolutions's average shareholder tangible equity for the quarter that ended in Mar. 2026 was €59.6 Mil. Therefore, Emergent BioSolutions's annualized Return-on-Tangible-Equity for the quarter that ended in Mar. 2026 was 39.51%.
The historical rank and industry rank for Emergent BioSolutions's Return-on-Tangible-Equity or its related term are showing as below:
STU:ER4'
s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: -595.63 Med: 15.71 Max: 556.12
Current: -10.66
During the past 13 years, Emergent BioSolutions's highest Return-on-Tangible-Equity was 556.12%. The lowest was -595.63%. And the median was 15.71%.
STU:ER4's Return-on-Tangible-Equity is ranked worse than 81.47% of 901
companies
in the Drug Manufacturers industry
Industry Median: 7.9
vs STU:ER4: -10.66
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net Income is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
Emergent BioSolutions Return-on-Tangible-Equity Related Terms
Emergent BioSolutions Return-on-Tangible-Equity Historical Data
* Premium members only.
The historical data trend for Emergent BioSolutions's Return-on-Tangible-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
STU:ER4 vs ELTP, NIKA, EOLS: Return-on-Tangible-Equity Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Emergent BioSolutions's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Emergent BioSolutions Return-on-Tangible-Equity vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Emergent BioSolutions's Return-on-Tangible-Equity distribution charts can be found below:
* The bar in red indicates where Emergent BioSolutions's Return-on-Tangible-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is four times the quarterly (Mar. 2026) net income data.
Return-on-Tangible-Equity is displayed in the 10-year financial page.
What does a Return-on-Tangible-Equity of 39.51% mean?
Emergent BioSolutions (STU:ER4) has a Return-on-Tangible-Equity of 39.51% as of Mar. 2026. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Emergent BioSolutions and its competitors. This is 151% above median its historical median of 15.71. According to the industry distribution chart, Emergent BioSolutions ranks #734 out of 901 companies in the Drug Manufacturers industry, placing it in the top 81.5%.
Is Emergent BioSolutions' Return-on-Tangible-Equity too high?
Emergent BioSolutions' current Return-on-Tangible-Equity of 39.51% is 151% above median its 10-year median of 15.71. The Drug Manufacturers industry median Return-on-Tangible-Equity is 7.90. Emergent BioSolutions' value of 39.51% is 400.1% above this industry median. Based on the distribution chart, Emergent BioSolutions ranks #734 out of 901 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Emergent BioSolutions has a GF Score™ of 61/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Emergent BioSolutions' Return-on-Tangible-Equity compare to ELTP and NIKA?
According to the Drug Manufacturers industry distribution chart, Emergent BioSolutions ranks #734 out of 901 companies for Return-on-Tangible-Equity. This places Emergent BioSolutions in the lower half of its industry. The industry median Return-on-Tangible-Equity is 7.90. Emergent BioSolutions' value of 39.51% is 400.1% above this benchmark. While the company's 10-year median is 15.71 vs. the industry median of 7.90, Emergent BioSolutions has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for a Drug Manufacturers company?
The median Return-on-Tangible-Equity among Drug Manufacturers companies is 7.90, based on 901 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Equity significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Emergent BioSolutions's current Return-on-Tangible-Equity of 39.51% is 400.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Emergent BioSolutions and its competitors. For the Drug Manufacturers industry, the median Return-on-Tangible-Equity is 7.90 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Emergent BioSolutions's current Return-on-Tangible-Equity is 39.51%, which is 151% above median its own 10-year median of 15.71. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Emergent BioSolutions stock overvalued right now?
Based on GuruFocus' analysis, Emergent BioSolutions (STU:ER4) is currently considered Significantly Overvalued. The stock's GF Value™ is €4.15, compared to a current price of €6.89 — trading 66% above its estimated fair value. The current Return-on-Tangible-Equity is 39.51%, which is 151% above median its 10-year median of 15.71 and 400.1% above the Drug Manufacturers industry median of 7.90. Emergent BioSolutions' overall GF Score™ is 61/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For Emergent BioSolutions (STU:ER4), the current Return-on-Tangible-Equity is 39.51% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Emergent BioSolutions (STU:ER4) Overvalued in 2026?
Based on GuruFocus' analysis, Emergent BioSolutions stock appears to be overvalued.
The current stock price of €6.89 is trading 66% above its estimated GF Value™ of €4.15.
GuruFocus considers Emergent BioSolutions to be Significantly Overvalued.
Key valuation signals for STU:ER4:
Return-on-Tangible-Equity: 39.51% (151% above median its 10-year median of 15.71)
GF Value™: €4.15 vs. price of €6.89 (66% above fair value)
Industry Position: 400.1% above the Drug Manufacturers median (#734 of 901)
No single metric tells the full story. See the STU:ER4 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Emergent BioSolutions Inc offers public health products to the government and healthcare providers. Company operates in three segments namely Commercial Product, MCM Products, and Services segment. The Commercial Product Segment consisting of Nasal Spray; the MCM Products Segment consisting of Anthrax-MCM products, Smallpox-MCM products and Other Products and the Services Segment consisting of Bioservices portfolio. Geographically, the company operates in United States, Canada, and Others. It derives maximum revenue from United states. The company's products include: NARCAN Nasal Spray, KLOXXADO Nasal Spray, ACAM2000, ANTHRASIL, BAT, BioThrax, CNJ-016, raxibacumab injection, Ebanga, and others.
61GF Score
Get the complete analysis for STU:ER4
Return-on-Tangible-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:ER4 has been successfully added to your 
